Table 2.
Imaging and pathological data of study subjects.
| Patient | Age (y) | Gender | CT result | NP-59 result | Pathological result | Followup improvement | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Appearance (side) | Size (mm) | Planar | SPECT | SPECT/CT | Finding | Size (mm) | ||||
| Control group (n = 9) | ||||||||||
| 1 | 50 | F | Nodule (L) | 20 | — | — | — | Adenoma | 21 | PAC, PRA, K |
| 2 | 34 | F | Nodule (L) | 18 | — | — | — | Adenoma | 16 | PAC, PRA, K, BP |
| 3 | 58 | F | Nodule (R) | 17 | — | — | — | Adenoma | 17 | PAC, PRA, K |
| 4 | 32 | F | Nodule (L) | 20 | — | — | — | Adenoma | 20 | PAC, K, BP |
| 5 | 71 | F | Nodule (L) | 17 | — | — | — | Adenoma | 25 | PAC, PRA, K, BP |
| 6 | 59 | M | Nodule (L) | 11 | — | — | — | Adenoma | 10 | PAC, BP |
| 7 | 60 | F | Nodule (R) | 21 | — | — | — | Adenoma | 20 | PAC, K |
| 8 | 72 | M | Nodule (R) | 22 | — | — | — | Adenoma | 20 | PAC, PRA, K, BP |
| 9 | 56 | F | Nodule (L) | 17 | — | — | — | Adenoma | 17 | PAC, K, BP |
| SPECT/CT group (n = 6) | ||||||||||
| 10 | 55 | F | Normal | — | N | R | R | Micronodule | 0.8 | PAC, K, BP |
| 11 | 48 | F | Nodule (L) | 17 | L | L | L | Adenoma | 17 | PAC, PRA, K, BP |
| 12† | 57 | M | Enlarge (L) | 9 (in thickness) | N | L | L | Focal nodular hyperplasia | 6 | PAC, PRA, K, BP |
| 13 | 56 | M | Nodule (L) | 12 | N | L | L | Adenoma | 10 | PAC, BP |
| 14 | 39 | M | Nodule (R) | 14 | N | R | R | Adenoma | 12 | PAC, K, BP |
| 15† | 27 | F | Normal | — | Faint | Bil | Bil | —# | —# | PAC, BP |
Abbreviations: CT: computed tomography; L: left; R: right; Bil: bilateral; other abbreviations are the same as Table 1.
†Patients 12 and 15 had stages 3 and 4 chronic kidney disease with serum creatinine level of 2.2 and 2.5 mg/dL, respectively.
#Patient 15 did not undergo adrenalectomy because of bilateral adrenal hyperplasia.